FDA: Reduce cefepime dose in patients with renal impairment

July 1, 2012

FDA issued a statement reminding healthcare professionals about the need to adjust the dosage of the antibacterial drug cefepime (Maxipime, Elan) in patients with renal impairment.

FDA issued a statement reminding healthcare professionals about the need to adjust the dosage of the antibacterial drug cefepime (Maxipime, Elan) in patients with renal impairment.

Cefepime may cause a specific type of seizure called nonconvulsive status epilepticus, primarily in patients with renal impairment who did not receive appropriate dosage adjustments of the drug.

To minimize the risk of seizures, FDA advised adjusting the cefepime dosage in patients with creatinine clearance ≤60 mL/min. If seizures associated with cefepime therapy occur, consider discontinuing cefepime or making appropriate dosage adjustments in patients with renal impairment.